2-benzamido-5-chlorothiazolo<5,4-b>pyridine | 131423-80-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-benzamido-5-chlorothiazolo<5,4-b>pyridine
• 英文别名: N-(5-chlorothiazolo[5,4-b]pyridin-2-yl)benzamide；N-(5-chloro[1,3]thiazolo[5,4-b]pyridin-2-yl)benzamide；N-(5-chloro-[1,3]thiazolo[5,4-b]pyridin-2-yl)benzamide
• CAS: 131423-80-8
• 化学式: C₁₃H₈ClN₃OS
• 分子量: 289.745
• InChiKey: LOADQEKXKUUQOQ-UHFFFAOYSA-N

物化性质

• 熔点：
  245 °C
• 密度：
  1.522±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  83.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-benzamido-5-chlorothiazolo<5,4-b>pyridine 在 硫酸 、 sodium hydroxide 作用下， 反应 2.0h， 以84%的产率得到5-氯-2-氨基噻唑[5,4-B]并吡啶
  参考文献：
  名称：

  [EN] FUSED BICYCLIC COMPOUNDS AS INHIBITORS FOR PI3 KINASE
  [FR] COMPOSÉS BICYCLIQUES FUSIONNÉS UTILISÉS COMME INHIBITEURS DE LA PI3 KINASE

  摘要：

  该发明涉及用于调节磷脂酰肌醇3-激酶活性及相关疾病的化合物（I）的公式。

  公开号：

  WO2010100144A1
• 作为产物：
  描述：

  3-氨基-2-溴-6-氯吡啶 在 copper(l) iodide 、 potassium carbonate 、 L-脯氨酸 作用下， 以 1,4-二氧六环 、 丙酮 为溶剂， 反应 19.0h， 生成 2-benzamido-5-chlorothiazolo<5,4-b>pyridine
  参考文献：
  名称：

  WO2019234243A5

  摘要：

  公开号：

  WO2019234243A5

文献信息

• [EN] FUSED BICYCLIC COMPOUNDS AS INHIBITORS FOR PI3 KINASE<br/>[FR] COMPOSÉS BICYCLIQUES FUSIONNÉS UTILISÉS COMME INHIBITEURS DE LA PI3 KINASE
  申请人：MERCK SERONO SA

  公开号：WO2010100144A1

  公开（公告）日：2010-09-10

  The invention relates to compounds of formula (I) for the regulation of phosphoinositides 3-kinases activity and related diseases.

  该发明涉及用于调节磷脂酰肌醇3-激酶活性及相关疾病的化合物（I）的公式。
• Prasad, V.S.R.; Sambaiah, T.; Reddy, K. Kondal, Synthetic Communications, 1990, vol. 20, # 13, p. 1983 - 1988
  作者：Prasad, V.S.R.、Sambaiah, T.、Reddy, K. Kondal

  DOI：——

  日期：——
• PRASAD, V. S. R.;SAMBAIAH, T.;REDDY, K. KONDAL, SYNTH. COMMUN., 20,(1990) N3, C. 1983-1988
  作者：PRASAD, V. S. R.、SAMBAIAH, T.、REDDY, K. KONDAL

  DOI：——

  日期：——
• NOVEL COMPOUNDS FOR DIAGNOSIS
  申请人：AC IMMUNE SA

  公开号：US20210252175A1

  公开（公告）日：2021-08-19

  The present invention relates to novel compounds that can be employed in the diagnosis, monitoring of disease progression or monitoring of drug activity of a group of disorders and abnormalities associated with alpha-synuclein (α-synuclein, A-synuclein, aSynuclein, a-synuclein, A-syn, α-syn, aSyn, SNCA, Non-amyloid beta component of Alzheimer's disease (AD) amyloid plaques, Non-A4 component of amyloid precursor, NACP) aggregates including, but not limited to, Lewy bodies and/or Lewy neurites, such as Parkinson's disease (PD). The instant compounds are particularly useful in the diagnosis of the preclinical state of such a disorder, monitoring residual disorder, or predicting the responsiveness of a patient who is suffering from such a disorder to the treatment with a certain medicament.
• [EN] NOVEL COMPOUNDS FOR DIAGNOSIS<br/>[FR] NOUVEAUX COMPOSÉS POUR DIAGNOSTIC
  申请人：AC IMMUNE SA

  公开号：WO2019234243A1

  公开（公告）日：2019-12-12

  The present invention relates to novel compounds that can be employed in the diagnosis, monitoring of disease progression or monitoring of drug activity of a group of disorders and abnormalities associated with alpha-synuclein (α-synuclein, A-synuclein, aSynuclein, a- synuclein, A-syn, α-syn, aSyn, SNCA, Non-amyloid beta component of Alzheimer's disease (AD) amyloid plaques, Non-A4 component of amyloid precursor, NACP) aggregates including, but not limited to, Lewy bodies and/or Lewy neurites, such as Parkinson's disease (PD). The instant compounds are particularly useful in the diagnosis of the preclinical state of such a disorder, monitoring residual disorder, or predicting the responsiveness of a patient who is suffering from such a disorder to the treatment with a certain medicament.